Axitinib is indicated for:
Population group: both men and women, only adults (18 years old or older)
Axitinib is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
For this indication, competent medicine agencies globally authorize below treatments (click for details):